Tumorigenesis of smoking carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone is related to its ability to stimulate thromboxane synthase and enhance stemness of non-small cell lung cancer stem cells

Yi Liu(University of Hong Kong), George G. Chen(Chinese University of Hong Kong), Bin Wu(Anhui Medical University), Shucai Yang(Southern Medical University Shenzhen Hospital), Jing Du(Sichuan University), Calvin S.H. Ng(Johnson & Johnson (United States)), Tony Mok(Chinese University of Hong Kong), Mingyue Li(Hunan University of Science and Technology), Run-Yue Huang(Guangzhou University of Chinese Medicine), Innes Y.P. Wan(Chinese University of Hong Kong), Malcolm J. Underwood(Bristol Royal Infirmary), Jun Wu(Wuhan University), Xiang Long(Peking University Shenzhen Hospital)
Cancer Letters
November 2, 2015
10.1016/j.canlet.2015.10.017
Cited by 18

Related Papers

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.4k